Difference between revisions of "How I Treat"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
=Malignant hematology= | =Malignant hematology= | ||
==Myeloid neoplasms== | ==Myeloid neoplasms== | ||
| − | ===[[:Category:Acute lymphoblastic leukemias|Acute lymphoblastic leukemia]]=== | + | ===[[:Category:Acute lymphoblastic leukemias|Acute lymphoblastic leukemia (ALL)]]=== |
*'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed] | *'''2023:''' Si Lim et al. [https://doi.org/10.1182/blood.2022016503 How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults] [https://pubmed.ncbi.nlm.nih.gov/37018730/ PubMed] | ||
*'''2023:''' Kopmar & Cassaday [https://doi.org/10.1182/blood.2022017035 How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/36548957/ PubMed] | *'''2023:''' Kopmar & Cassaday [https://doi.org/10.1182/blood.2022017035 How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/36548957/ PubMed] | ||
| Line 16: | Line 16: | ||
*'''2015:''' Frey & Luger. [https://doi.org/10.1182/blood-2014-09-551937 How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/25966988/ PubMed] | *'''2015:''' Frey & Luger. [https://doi.org/10.1182/blood-2014-09-551937 How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia] [https://pubmed.ncbi.nlm.nih.gov/25966988/ PubMed] | ||
| − | ===[[Acute myeloid leukemia]]=== | + | ===[[Acute myeloid leukemia|Acute myeloid leukemia (AML)]]=== |
*'''2023:''' Biederstädt & Rezvani [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | *'''2023:''' Biederstädt & Rezvani [https://doi.org/10.1182/blood.2021012411 How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy] [https://pubmed.ncbi.nlm.nih.gov/35512203/ PubMed] | ||
*'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed] | *'''2021:''' Falini et al. [https://doi.org/10.1182/blood.2020008211 How I diagnose and treat NPM1-mutated AML] [https://pubmed.ncbi.nlm.nih.gov/33171486/ PubMed] | ||
| Line 26: | Line 26: | ||
*'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed] | *'''2011:''' Bakst et al. [https://doi.org/10.1182/blood-2011-04-347229 How I treat extramedullary acute myeloid leukemia] [https://pubmed.ncbi.nlm.nih.gov/21795742/ PubMed] | ||
| − | ===[[Chronic myeloid leukemia]]=== | + | ===[[Chronic myeloid leukemia|Chronic myeloid leukemia (CML)]]=== |
*'''2022:''' Berman [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia] | *'''2022:''' Berman [https://doi.org/10.1182/blood.2021011722 How I treat chronic-phase chronic myelogenous leukemia] | ||
| − | ===[[Myelodysplastic syndrome]]=== | + | ===[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]=== |
*'''2019:''' Santini [https://doi.org/10.1182/blood-2018-03-785915 How I treat MDS after hypomethylating agent failure] | *'''2019:''' Santini [https://doi.org/10.1182/blood-2018-03-785915 How I treat MDS after hypomethylating agent failure] | ||
*'''2013:''' Sekeres & Cutler [http://www.bloodjournal.org/content/123/6/829.long How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed] | *'''2013:''' Sekeres & Cutler [http://www.bloodjournal.org/content/123/6/829.long How we treat higher-risk myelodysplastic syndromes] [https://pubmed.ncbi.nlm.nih.gov/24363399/ PubMed] | ||
*'''2013:''' Fenaux & Adès [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes] | *'''2013:''' Fenaux & Adès [https://doi.org/10.1182/blood-2013-02-453068 How we treat lower-risk myelodysplastic syndromes] | ||
| − | ===[[Polycythemia vera]]=== | + | ===[[Polycythemia vera|Polycythemia vera (PV)]]=== |
*'''2014:''' Vannucchi [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed] | *'''2014:''' Vannucchi [https://doi.org/10.1182/blood-2014-07-551929 How I treat polycythemia vera] [https://pubmed.ncbi.nlm.nih.gov/25278584/ PubMed] | ||
Revision as of 01:46, 7 September 2023
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered high-level expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.
Articles are presented by condition, in reverse chronological order. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Note: this page is currently under construction.
Malignant hematology
Myeloid neoplasms
Acute lymphoblastic leukemia (ALL)
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2023: Kopmar & Cassaday How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Douer. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Forman. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy PubMed
- 2019: Ravandi How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia PubMed
- 2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults PubMed
- 2015: Frey & Luger. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia PubMed
Acute myeloid leukemia (AML)
- 2023: Biederstädt & Rezvani How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy PubMed
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML PubMed
- 2020: DeWolf & Tallman How I treat relapsed or refractory AML PubMed
- 2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs PubMed
- 2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities PubMed
- 2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia PubMed
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2011: Bakst et al. How I treat extramedullary acute myeloid leukemia PubMed
Chronic myeloid leukemia (CML)
Myelodysplastic syndrome (MDS)
- 2019: Santini How I treat MDS after hypomethylating agent failure
- 2013: Sekeres & Cutler How we treat higher-risk myelodysplastic syndromes PubMed
- 2013: Fenaux & Adès How we treat lower-risk myelodysplastic syndromes
Polycythemia vera (PV)
- 2014: Vannucchi How I treat polycythemia vera PubMed
Lymphoid neoplasms
Chronic lymphocytic leukemia (CLL/SLL)
- 2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
- 2019: Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 21;133(12):1298-1307. link to PMC article
- 2018: Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018 Jan 25;131(4):379-386. link to original article PubMed
Classical Hodgkin lymphoma (cHL)
- 2021: Epperla & Herrera How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
Diffuse large B-cell lymphoma (DLBCL)
- 2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting PubMed